NASDAQ:BOLT
Bolt Biotherapeutics, Inc. Stock News
$1.10
-0.0200 (-1.79%)
At Close: May 02, 2024
Bolt Biotherapeutics to Present at the TD Cowen 44th Annual Healthcare Conference
07:00am, Tuesday, 27'th Feb 2024
REDWOOD CITY, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, to
REDWOOD CITY, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company pioneering novel immuno-oncology therapeutics for the trea
Bolt Biotherapeutics to Participate in September Investor Conferences
04:15pm, Tuesday, 05'th Sep 2023
REDWOOD CITY, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, t
Bolt Biotherapeutics to Present at BTIG Virtual Biotechnology Conference 2023
05:27pm, Monday, 31'st Jul 2023
REDWOOD CITY, Calif., July 31, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immuno-oncology therapeutics for the treatment
Comprehensive Phase 1 data at ASCO support initiation of two Phase 2 trials Comprehensive Phase 1 data at ASCO support initiation of two Phase 2 trials
Bolt Biotherapeutics to Present Preclinical Data for BDC-3042, a Dectin-2-Targeting Agonistic Antibody, at 2023 AACR Annual Meeting
04:30pm, Tuesday, 14'th Mar 2023
REDWOOD CITY, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immuno-oncology therapeutics for the treatment
Bolt Biotherapeutics to Present at Cowen 43rd Annual Healthcare Conference
08:00am, Tuesday, 28'th Feb 2023
REDWOOD CITY, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immuno-oncology therapeutics for the treatment
Bolt Biotherapeutics to Present at February Investor Conferences
08:00am, Wednesday, 01'st Feb 2023
REDWOOD CITY, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immuno-oncology therapeutics for the treatment
Bolt Biotherapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference
07:30am, Wednesday, 31'st Aug 2022
REDWOOD CITY, Calif., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immuno-oncology therapeutics for the treatment
Bolt Biotherapeutics: A Promised Follow Up
03:24pm, Friday, 26'th Aug 2022
Today, we post a promised follow-up on early stage biotech concern Bolt Biotherapeutics. The company has suffered some setbacks over the past year, but the stock now trades for approximately one-third
Bolt, Orion-E to build solar plants in Brazil for about $630 million
04:34pm, Tuesday, 23'rd Aug 2022
Energy infrastructure company Orion-E has reached an agreement with energy trader Bolt to build solar photovoltaic plants in Brazil with a combined capacity of 500 megawatts (MW), a company executive
Bolt Biotherapeutics to Present Ex Vivo Data Characterizing the Myeloid Cell Landscape in Solid Tumors at ASCO 2022
08:00am, Friday, 27'th May 2022
- Ex vivo data support the high frequency of myeloid cells in tumors, even when T cells are not present -
Hot Penny Stocks to Watch Now? 3 For Your List
06:15pm, Thursday, 12'th May 2022
Are these hot penny stocks on your list right now? The post Hot Penny Stocks to Watch Now?
5 Biotech Stocks Set to Outpace Q1 Earnings Estimates
09:02am, Wednesday, 11'th May 2022
Let us take a look at some drug/biotech stocks, ANGN, APLT, BOLT, IKNA and LABP, which are poised to beat on first-quarter earnings.
Bolt Biotherapeutics to Present at 21st Annual Needham Healthcare Conference
08:00am, Thursday, 07'th Apr 2022
REDWOOD CITY, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology therapeutics that combine